Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 2C9 2 and 3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.

Clinical pharmacology and therapeutics - 1 Feb 2008

Becker M L, Visser L E, Trienekens P H, Hofman A, van Schaik R H N, Stricker B H Ch

Abstract excerpt

Sulfonylurea hypoglycemics are mainly metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme. The CYP2C9*2 and *3 polymorphisms encode proteins with less enzymatic activity and are correlated with elevated serum levels of sulfonylurea, as demonstrated in healthy volunteers. In this study, the effect of these variants is described for patients with diabetes mellitus treated with sulfonylurea. Associations between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Blood Glucose

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Diabetes Mellitus, Type 2

Share to Dose-Response Relationship, Drug

Share to Hypoglycemic Agents

Share to Population Surveillance

Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 17597710
DOI: 10.1038/sj.clpt.6100273

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.PMID 17597710Read ↗

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.Semantic proximity Read ↗

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.Semantic proximity Read ↗

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.Semantic proximity Read ↗

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.Semantic proximity Read ↗

Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphismsSemantic proximity Read ↗

CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.Semantic proximity Read ↗

Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients.Semantic proximity Read ↗

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.Semantic proximity Read ↗

Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment.Semantic proximity Read ↗

Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.Semantic proximity Read ↗

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.Semantic proximity Read ↗

CYP2C19 Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 DiabetesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.